Neurofibromatosis Type 2 name change
22 September 2023
THE NEW NAME FOR NEUROFIBROMATOSIS TYPE 2 IS NF2-RELATED-SCHWANNOMATOSIS (NF2).
The name change reflects the fact that neurofibromas do not occur in NF2 and therefore the name neurofibromatosis is factually incorrect. When previous tumour pathology tests are reviewed these are definitely not neurofibroma although a cross over tumour called a hybrid tumour is sometimes seen in NF2-related and other schwannomatosis. The continued naming of NF2 as a neurofibromatosis only causes confusion with NF1 even amongst the medical profession.
Although the committee did look into changing the gene symbol, the Human Genome Naming Commission felt that the symbol was too long standing in the literature but did agree to changing the gene name to NF2 -Moesin Ezrin Radixin like (MERLIN) tumour suppressor from the previously highly inaccurate 'neurofibromin 2'.
As such, we have now changed all the schwannomatosis conditions to reflect the underlying gene, thus: NF2-related-schwannomatosis, SMARCB1 related schwannomatosis, LZTR1 elated schwannomatosis, 22q related schwannomatosis and schwannomatosis NOS (Not otherwise specified).
We recognise that other tumour types occur and may even be the most important in some individuals such as meningiomas and ependymomas but the committee felt NF2 related schwannomatosis was the best and most pragmatic option.
We at Nerve Tumours UK are in the process of updating our medical publications and resources in print and digital where relevant. This will however not be reflected in our news section and other non medical publications digital and print.
Filter News

No Laughing Matter
Tom is a former journalist, here he describes his journey from music journalism to comedy, & what his NF2 has to do with it
Read More
Shine A Light on Neurofibromatosis 2020
Find out what we're up to for our Shine A Light campaign this year!
Read More
Statement by Michael Fry our Chair of the Board of Trustees
The impact of the corona virus on the charity sector and Nerve Tumours UK's continued support to those affected by NF
Read More
NF1, Plexiform Neurofibromas Market Research Study
Find out more about an NF1, Plexiform Neurofibromas market research survey
Read More
Statement by Rachel Jones & Rebecca Rennison our Specialist Neurofibromatosis Nurses UK
A statement on coronavirus by Rachel Jones & Rebecca Rennison specialist Neurofibromatosis nurses in the North East & Cumbria
Read More
Statement by Samantha Gaden our Specialist Neurofibromatosis Nurse UK
A statement on coronavirus by Samantha Gaden specialist Neurofibromatosis nurse in the North West
Read More
Statement by Melanie Murrell our Specialist Neurofibromatosis Nurse UK
A statement on coronavirus by Melanie Murrell specialist Neurofibromatosis nurse in the West Midlands
Read More
Statement by Carolyn Smyth Lead Specialist Neurofibromatosis Nurse UK
A Statement on Coronavirus by Carolyn Smyth Lead Specialist Neurofibromatosis Nurse UK
Read More
COVID - 19 News from Children’s Tumour Foundation our partners in the US
Covid - 19 News from Children's Tumour Foundation our partners in the US
Read More